Headshot of Hunter Land

Hunter Land, PhD
Chief Executive Officer
Lupvindol Biosciences Limited
ADVISORY BOARD MEMBER
SCIENCE

BIO
Hunter Land, PhD, MS is the Vice President of Research & Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Dr. Land acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation, the world’s largest cannabis producer. Most notably, he was GW Pharma's first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® (FDA-approved prescription CBD) and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), multiple sclerosis, and pain. Dr. Land has presented at over 50 scientific conferences, is a named inventor on nine patent applications, and has over 20 publications. In addition, he serves as a guest lecturer at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy, and has been featured in Forbes and Entrepreneur as a cannabinoid subject matter expert. Dr. Land also holds several other important positions, including Chief Scientific Officer of the National Hockey League Alumni/NEEKA Brain Health, Executive Board Member at Alterola Biotech, Scientific Advisory Board Member at Nalu Biosciences, Veterinary Cannabis Society, CannMed, the Council for Federal Cannabis Regulation, and co-founder of the Cannabinoid Education Working Group.
Image